account_id none on file
legal_name Matinas BioPharma Holdings, Inc.
ticker MTNB
cik 1582554
domain matinasbiopharma.com
linkedin_company_url https://www.linkedin.com/company/matinas-biopharma
entry_point_account_id none on file
name Matinas Biopharma Holdings Inc.
exchange NYSE
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 1 executives 9 family 0
why_nownone on file
callsnone on file
filings
reduction in force. General and Administrative expenses. General and Administrative (G&A) expenses for the three months ended March 31, 2026 and 2025 were $1,936 and $1,861, respectively.
filing / May 8, 2026 / receipt
executives
| Dominick M. DiPaolo | Senior Vice President | - | receipt |
| Douglas F. Kling | Senior Vice President | - | receipt |
| James J. Ferguson III | Chief Medical Officer | - | receipt |
| Jerome D. Jabbour | President | - | receipt |
| Keith Kucinski | Chief Financial Officer | - | receipt |
| Natasha Giordano | director | - | receipt |
| Raphael J. Mannino | Chief Scientific Officer | - | receipt |
| Robin Smith | director | - | receipt |
| Thomas Hoover | Chief Business Officer | - | receipt |
familynone on file
upcoming
| 2026-11-09 | earnings call | scheduled | ir |
changes
| 2025-02-13 | director, appointed | sec_8k |
| 2021-12-06 | Chief Business Officer, appointed | sec_8k |
| 2020-09-15 | director, appointed | sec_8k |
| 2019-02-25 | Chief Medical Officer, appointed | sec_8k |
| 2019-01-03 | Chief Financial Officer, appointed | sec_8k |
| 2017-04-18 | Senior Vice President, appointed | sec_8k |
| 2016-10-13 | Chief Scientific Officer, appointed | sec_8k |
| 2016-03-09 | President, appointed | sec_8k |
| 2015-09-01 | Senior Vice President and Chief Technology Officer, appointed | sec_8k |
| 2015-03-18 | Senior Vice President, appointed | sec_8k |
mcp_package_hint
slug matinas-biopharma-holdings-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$